CyPep-O1 has potential as a novel targeted treatment for multiple cancers and acts through targeted tumour-cell killing and by inducing an anti-tumour immune response.
CyPep-O1 has the potential to eliminate cancer cells by targeted cell-killing and by inducing a long-lasting tumour-specific immune response. CyPep-01 selectively targets and lyses tumour cells while leaving healthy cells intact. As cancer cells break down, tumour-specific particles (antigens) are released into the circulation where they are recognised by the immune system and activate the anti-tumour immune response. The described mode of action of this broad-spectrum product has been validated through extensive pre-clinical testing and applies across multiple types of cancer. Currently, CyPep-01 is in the final phases of pre-clinical testing with the aim of advancing into clinical studies.
This eliminates cancer cells and induces a cancer specific immune response. CyPep-O1 selectively targets- and lyses cancer cells while leaving healthy cells intact. This releases cancer specific particles (antigens), providing in-situ immunization. The described mode of action of this broad-spectrum product has been validated through extensive preclinical testing and applies to subtypes across multiple different types of cancer. Currently, CyPep-O1 is in the final fases of preclinical toxicology testing.
Cytovation is developing CyPep-O1 for intratumoral injection. There are no systemic side effects or risk of infection. This target profile is clearly superior to existing treatment alternatives (e.g lytic virus) and can become the gold standard for tumour immunization approaches, with blockbuster potential. CyPep-O1 can be used as single agent therapy or in combination with checkpoint inhibitors targeting PD-(L)1 or CTLA4.
Building on strong preclinical data, Cytovation is seeking funding to pursue phase I and phase II clinical development and establish proof-of-concept in patients. The PoC milestone should represent a very significant valuation boost for the company, opening favorable scenarios for continued development or partnership with established industry players. Strong patent protection provides a unique opportunity for significant return-on-investment given the market-transforming potential of this unique product.
Proprietary peptide consisting of 27 amino acids
Novel two-stage mode of action that selectively targets and kill tumour cells
As cancer cells break down, tumour-specific antigens are released into the circulation where they are recognised by the immune system and activate the anti-tumour immune response
Currently in pre-clinical development following extensive testing and quality controls
CyPep-1 has claims granted both to the peptide itself and to specific medical uses of the peptide across Europe and USA.
© 2018 Cytovation AS|All Rights Reserved